@article{3021440,
    title = "Pericardial synovial sarcoma: Case report, literature review and pooled analysis",
    author = "Duran-Moreno, J. and Kampoli, K. and Kapetanakis, E.I. and Mademli, M. and Koufopoulos, N. and Foukas, P.G. and Kostopanagiotou, K. and Tomos, P. and Koumarianou, A.",
    journal = "In vivo (Athens, Greece)",
    year = "2019",
    volume = "33",
    number = "5",
    pages = "1531-1538",
    publisher = "International Institute of Anticancer Research",
    doi = "10.21873/invivo.11633",
    keywords = "anthracycline;  carcinoembryonic antigen;  cytokeratin 18;  cytokeratin 19;  cytokeratin 7;  cytokeratin 8;  cytokeratin AE1;  cytokeratin AE3;  doxorubicin;  epithelial cell adhesion molecule;  epithelial membrane antigen;  ifosfamide;  Ki 67 antigen;  pazopanib;  protein p53;  vimentin, adult;  Article;  cancer chemotherapy;  cancer surgery;  cardiovascular magnetic resonance;  case report;  clinical article;  cytoreductive surgery;  dyspnea;  fatigue;  follow up;  human;  maintenance therapy;  male;  middle aged;  minimal residual disease;  molecularly targeted therapy;  multidisciplinary team;  multiple cycle treatment;  pericardial disease;  pericardial effusion;  pericardial synovial sarcoma;  positron emission tomography;  stereotactic radiosurgery;  superior cava vein;  surgical approach;  synovial sarcoma;  biopsy;  immunohistochemistry;  mortality;  nuclear magnetic resonance imaging;  pathology;  pericardium;  radiosurgery;  synovial sarcoma, Biopsy;  Humans;  Immunohistochemistry;  Magnetic Resonance Imaging;  Male;  Middle Aged;  Pericardial Effusion;  Pericardium;  Positron-Emission Tomography;  Radiosurgery;  Sarcoma, Synovial",
    abstract = "Background: Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. Case Report: We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. Materials and Methods: Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months. Conclusion: Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future. © 2019 International Institute of Anticancer Research. All rights reserved."
}